<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate differences in <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidizability by glycemic status within the <z:hpo ids='HP_0000855'>Insulin Resistance</z:hpo> <z:hpo ids='HP_0002621'>Atherosclerosis</z:hpo> Study cohort </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidizability (lag time and oxidation rate) after exposure to copper was compared among 352 subjects with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (NGT), <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT), newly diagnosed type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and known type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: After adjustment for age, clinic, ethnicity, sex, and smoking status, <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidation rates differed by glycemic status (P = 0.001), with a strong trend (P = 0.0001) for reduced <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidation rate with increasing extent and duration of <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> (2,378 +/- 54, 2,208 +/- 65, 2,145 +/- 71, and 2,115 +/- 48 arbitrary units [mean +/- SE] for NGT, IGT, newly diagnosed type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and known type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, respectively) </plain></SENT>
<SENT sid="3" pm="."><plain>Differences in <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidation rate among groups were relatively unaltered by adjustment for <z:chebi fb="23" ids="18059">lipids</z:chebi> and <z:chebi fb="2" ids="6495">lipoproteins</z:chebi>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, BMI, and waist-to-hip ratio (WHR) and remained significant even after further adjustment for dietary <z:chebi fb="11" ids="22586">antioxidants</z:chebi> and fatty acids, as well as medications </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="15" ids="39026">LDL</z:chebi> lag times differed marginally by glycemic status (P = 0.058), with similar values for NGT, IGT, and newly diagnosed type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (57-60 min) but higher values for known type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (65 +/- 2) </plain></SENT>
<SENT sid="5" pm="."><plain>These differences were eliminated by further adjustment for <z:chebi fb="23" ids="18059">lipids</z:chebi> and <z:chebi fb="2" ids="6495">lipoproteins</z:chebi>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, BMI, and WHR </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: We found that glycemic status influenced <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidizability, with a paradoxical reduction in <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidizability, as indicated by a lower <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidation rate with increased extent and duration of <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>This difference was only slightly attenuated by adjustment for relevant demographic, metabolic, dietary, and pharmacological factors that potentially influence <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidation </plain></SENT>
</text></document>